Teva 的 3 期研究证实了 AJOVY 的有效性和安全性。 Teva's Phase 3 study confirms AJOVY's efficacy and safety.

Teva Pharmaceuticals 的 3 期研究证实了 AJOVY 在预防中国成年患者偏头痛方面的有效性和安全性，减少了每月偏头痛天数，并表现出优于安慰剂的疗效。 Teva Pharmaceuticals' Phase 3 study confirms AJOVY's efficacy and safety in preventing migraines in adult Chinese patients, reducing monthly migraine days and demonstrating superior efficacy over placebo. AJOVY 是一种人源化单克隆抗体，耐受性良好，未观察到安全信号。 AJOVY, a humanized monoclonal antibody, is well-tolerated and has no safety signals observed. 该结果与之前的第三阶段数据一致，该数据分别于 2018 年和 2019 年获得美国和欧盟的批准。 The results align with previous Phase 3 data, which led to U.S. and EU approvals in 2018 and 2019, respectively.